Particle.news
Health ❯ Healthcare ❯ Clinical Trials
Patient Outcomes Combination Therapy Weight Loss Results Weight Loss Medications Semaglutide Side Effects Weight Loss Drugs Patient Safety Weight Loss Studies Weight Loss Outcomes GLP-1 Receptor Agonists Comparative Studies Wegovy Lenacapavir Wegovy Trials Cognitive Decline Weight Loss Trials Lecanemab Trials Zepbound Real-World Evidence Phase 3 Trials Baxdrostat Obesity Treatments Orforglipron Alzheimer's Treatments Semaglutide Trials Weight Management Lecanemab Leqembi Novo Nordisk Evidence-Based Medicine LDL Cholesterol Reduction Zenith Trial Mifepristone Complications Cardiovascular Outcomes Retatrutide Brepocitinib Placebo-Controlled Trials Probenecid in PKD SGLT-2 Inhibitors EMPACT-MI Trial Nuzolvence and Blujepa Ruxolitinib Trials Orforglipron Study Semaglutide Studies Lecanemab and Donanemab Weight-loss Injections COPD Treatments Lynkuet Weight Maintenance Lipfendra Trials Statin Therapy Capivasertib Trials Solriamfetol Pembrolizumab Late-Stage Trials Survival Rates Orforglipron vs Semaglutide Placebo Effect Vutrisiran Cognitive Impairment Retatrutide Trials Weight Regain Studies FDA Approval Process CagriSema Skin Clearance Elamipretide Obicetrapib Cardiovascular Protection Semaglutide and Tirzepatide STEP UP Trial Head-to-Head Trials Tzield Study Results Addyi Fampridine Trials Semaglutide Study Ubrogepant Influenza Prevention Monoclonal Antibodies International Studies Teplizumab Trials Zumilokibart Expert Opinions Phase Three Trials Hympavzi Talazoparib and Enzalutamide Sub-Saharan Africa Mounjaro Trials Pre-exposure Prophylaxis (PrEP) Wegovy Study Results Wegovy Clinical Trial Hidradenitis Suppurativa Nirsevimab Trials Myotonic Dystrophy Type 1 Tumor Growth Orforglipron Study Results COVID-19 Studies Weight Loss Injections Tirzepatide Study Asthma Exacerbations
The company says it will use its global development and commercial reach to advance Apogee’s antibody programs targeting IL-13 and a combo that blocks TSLP.
